Thu, March 9, 2017
Wed, March 8, 2017

David Nierengarten Reiterated (ANAB) at Buy and Held Target at $28 on, Mar 9th, 2017

David Nierengarten of Wedbush, Reiterated "AnaptysBio, Inc." (ANAB) at Buy and Held Target at $28 on, Mar 9th, 2017.

David has made no other calls on ANAB in the last 4 months.



There is 1 other peer that has a rating on ANAB. Out of the 1 peers that are also analyzing ANAB, 0 agree with David's Rating of Hold.



This is the rating of the analyst that currently disagrees with David


  • Kennen MacKay of "Credit Suisse" Initiated at Buy and Held Target at $34 on, Tuesday, February 21st, 2017